Further, Jiang et al. developed lipid-like particles (LLN) to deliver Cas9 mRNA and sgRNA targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene for the treatment of hypercholesterolemia. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.